Canada markets closed

Delcath Systems, Inc. (DCTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.67-0.15 (-2.20%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close6.82
Open6.87
Bid5.03 x 800
Ask6.80 x 1200
Day's Range6.60 - 6.87
52 Week Range6.44 - 25.18
Volume14,523
Avg. Volume97,504
Market Cap49.066M
Beta (5Y Monthly)0.42
PE Ratio (TTM)N/A
EPS (TTM)-4.25
Earnings DateMar. 29, 2022 - Apr. 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.80
  • GlobeNewswire

    Delcath Systems to Present at the H.C. Wainwright BioConnect Virtual Investor Conference on January 10, 2022

    NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will participate in an upcoming virtual investor conference: H.C. Wainwright BioConnect Virtual Investor Conference January 10-13, 2022 Presentation Date and Time: On-demand beginning January 10, 2022 at 7:00 AM (ET)Webcast: https://journey.ct.events/view/f57806c5-e3e7-4120-85c6-37ab9b15d12

  • GlobeNewswire

    Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis

    On final analysis of the primary overall response (ORR) endpoint, HEPZATO further exceeded the predefined threshold for success with a median duration of response of 14 months While overall survival data continues to mature, a Hazard Ratio (HR) analysis of survival at 12-months yielded a statistically significant advantage for HEPZATO over a Best Alternative Care (BAC) arm [HR=0.37, p=0.01] in patients who received one or more treatments HEPZATO had statistically significant improvements over BA

  • GlobeNewswire

    Delcath Systems Provides Speaker List for Dec 2, 2021 Investor Update Meeting

    Focus Trial Data and Future Development Plans to be Discussed by Management and KOLsNEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today its agenda and distinguished speaker list for a comprehensive Investor Update Meeting taking place Thursday, December 2nd , from 10:00am ET – 1:30pm EST. The event will focus on the company’s US product candida